ENG
Analgesics Market: Global Industry Analysis and Forecast (2024-2030) by Type, Route of Administration and, Region
The Analgesics Market size was valued at US$ 26.76 Billion in 2023 and the Analgesics revenue is expected to grow at 1.4 % through 2024 to 2030, reaching nearly US$ 29.50 Billion.
Format : PDF | Report ID : SMR_498
Analgesics Market Definition & Overview:
Analgesics, or painkillers, are drugs that are used to treat and relieve pain in the body. They're usually utilized when the pain is extreme and the sufferer can't stand it any longer. Non-opioids, opioids, and compound analgesics (a mix of opioids and non-opioids) are the most often used topical analgesics worldwide. The rise in acute and chronic illnesses, as well as the growing prevalence of cancer globally, are largely responsible for the development of pain treatment, pain management, and painkillers. Analgesics Market report's segment analysis is completed on the basis of type, route of administration and region.
To get more Insights: Request Free Sample Report
Analgesics Market Dynamics:
The worldwide analgesics market is predicted to increase moderately in the next years, owing to reasons such as rising rates of cardiovascular disease, cancer, and arthritis, as well as an aging population. Another element that aids market growth is the recurrent discomfort and pains experienced by the aging population. In addition, the analgesics market is likely to benefit from increased governmental and private sector R&D spending, with a focus on the classes of compounds for developing novel treatments.
Additionally, increased government initiatives for better chronic pain prevention and management are boosting the market growth. Moreover, the rising occurrence of physiological injuries, phantom pains, and operations in China and India is driving up sales.
However, uncontrolled opioid prescriptions, drug addiction, and unregulated government policies are anticipated to stifle the global analgesics market's growth.
Analgesics Market Segment Analysis:
By Type, The market for nonsteroidal anti-inflammatory medications (NSAIDs) is expected to increase quickly, with a CAGR of 4.1 percent between 2024 and 2030. A significant element driving the segment's rise is a growing emphasis on preventing the diversion of prescribed opioid prescriptions.
By Route of Administration, Further examination of revenue generated by the various sectors reveals that oral injection is the fastest-growing segment, with a CAGR of 2.41 percent through 2030. Because of the approval of several over-the-counter (OTC) analgesics that do not require a prescription, the oral variety is gaining economic traction with increased sales. Oral analgesics are widely available in pharmacies across the world in various forms such as capsules and pills.
Analgesics Market Regional Insights:
With 38.8% of worldwide analgesics market demand in 2023, APAC is expected to be the most profitable region for the analgesics cosmetics market. The enormous wealth of this region may be attributed to a number of sources, including - Crocin, manufactured by GlaxoSmithKline Asia Private Limited (GSKAP), which is India's biggest analgesics brand, with liquid and solid versions available. With over two million pills sold every day in India and over 20 tablets sold per second, it falls under the non-prescription (OTC) category. This alone is a major influencer in the APAC analgesics market, supported greatly by the widespread practice of self-medication.
Taking into account China's densely populated economy, ChinaPower claims that the Chinese population is aging at a quicker pace than the rest of the globe. The one-child policy in China, along with rapid advances in health care, has resulted in a rise in life expectancy and a drop in the birth rate, resulting in an increase in the elderly population who rely on the analgesic medication market.
The objective of the report is to present a comprehensive analysis of the Analgesics Market to the stakeholders in the industry. The report provides trends that are most dominant in the Analgesics Market and how these trends will influence new business investments and market development throughout the forecast period. The report also aids in the comprehension of the market dynamics and competitive structure of the market by analyzing market leaders, market followers, and regional players.
The qualitative and quantitative data provided in the Analgesics Market report is to help understand which market segments, regions are expected to grow at higher rates, factors affecting the market, and key opportunity areas, which will drive the industry and market growth through the forecast period. The report also includes the competitive landscape of key players in the industry along with their recent developments in the Analgesics Market. The report studies factors such as company size, market share, market growth, revenue, production volume, and profits of the key players in the market.
The report provides Porter's Five Force Model, which helps in designing the business strategies in the market. The report helps in identifying how many rivals are existing, who they are, and how their product quality is in the Market. The report also analyses if the Analgesics Market is easy for a new player to gain a foothold in the market, do they enter or exit the market regularly if the market is dominated by a few players, etc.
Analgesics Market Scope:
|
Analgesics Market |
|
|
Market Size in 2023 |
USD 26.76 Bn. |
|
Market Size in 2030 |
USD 29.50 Bn. |
|
CAGR (2024-2030) |
1.4% |
|
Historic Data |
2018-2022 |
|
Base Year |
2023 |
|
Forecast Period |
2024-2030 |
|
Segment Scope |
by Type
|
|
by Route of Administration
|
|
|
Regional Scope |
North America- United States, Canada, and Mexico Europe – UK, France, Germany, Italy, Spain, Sweden, Austria, and Rest of Europe Asia Pacific – China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC Middle East and Africa - South Africa, GCC, Egypt, Nigeria, Rest of the Middle East and Africa South America – Brazil, Argentina, Rest of South America |
Analgesics Market Key Players:
- Pfizer Inc. (USA)
- Sun Pharmaceutical Industries, Inc. (Mumbai)
- Sanofi SA (France)
- AbbVie Inc. (Allergan plc) (USA)
- Teva Pharmaceuticals (Jerusalem)
- Janssen Pharmaceuticals, Inc. [Johnson & Johnson] (Belgium)
- Endo Pharmaceuticals Inc. (Ireland)
- Purdue Pharmaceuticals L.P. (USA)
- Assertio Therapeutics, Inc. (USA)
- Mallinckrodt Pharmaceuticals (USA)
- Bayer AG (Germany)
- GlaxoSmithKline plc. (UK)
- Bausch Health Companies Inc. (Canada)
- Novartis AG (Switzerland)
Frequently Asked Questions
The worldwide analgesics market is predicted to increase moderately in the next years, owing to reasons such as rising rates of cardiovascular disease, cancer, and arthritis, as well as an aging population.
With 38.8% of worldwide analgesics market demand in 2023, APAC is expected to be the most profitable region for the analgesics cosmetics market.
The one-child policy in China, along with rapid advances in health care, has resulted in a rise in life expectancy and a drop in the birth rate, resulting in an increase in the elderly population who rely on the analgesic cosmetic market.
Pfizer Inc. (USA), Sun Pharmaceutical Industries, Inc. (Mumbai), Sanofi SA (France), AbbVie Inc. (Allergan plc) (USA), and Teva Pharmaceuticals (Jerusalem).
Chapter 1 Scope of the Report
Chapter 2 Research Methodology
2.1. Research Process
2.2. Global Analgesics Market: Target Audience
2.3. Global Analgesics Market: Primary Research (As per Client Requirement)
2.4. Global Analgesics Market: Secondary Research
Chapter 3 Executive Summary
Chapter 4 Competitive Landscape
4.1. Market Share Analysis, By Region, 2023-2030(In %)
4.1.1.1. North America Market Share Analysis, By Value, 2023-2030 (In %)
4.1.1.2. Europe Market Share Analysis, By Value, 2023-2030 (In %)
4.1.1.3. Asia Pacific Market Share Analysis, By Value, 2023-2030 (In %)
4.1.1.4. South America Market Share Analysis, By Value, 2023-2030 (In %)
4.1.1.5. Middle East and Africa Market Share Analysis, By Value, 2023-2030 (In %)
4.2. Market Dynamics
4.2.1.Market Drivers
4.2.2.Market Restraints
4.2.3.Market Opportunities
4.2.4.Market Challenges
4.2.5.PESTLE Analysis
4.2.6.PORTERS Five Force Analysis
4.2.7.Value Chain Analysis
4.3. Global Analgesics Market Segmentation Analysis, 2023-2030 (Value US$ MN)
4.3.1.1. Global Market Share Analysis, By Type, 2023-2030 (Value US$ MN)
4.3.1.1.1. Non-opioids
4.3.1.1.2. Opioids
4.3.1.2. Global Market Share Analysis, By Route of Administration, 2023-2030 (Value US$ MN)
4.3.1.2.1.Oral
4.3.1.2.2.Intravenous
4.3.1.2.3.Rectal
4.3.1.2.4.Transdermal
4.3.1.2.5.Topical
4.4. North America Analgesics Market Segmentation Analysis, 2023-2030 (Value US$ MN)
4.4.1.1. North America Market Share Analysis, By Type, 2023-2030 (Value US$ MN)
4.4.1.1.1.Non-opioids
4.4.1.1.2.Opioids
4.4.1.2. North America Market Share Analysis, By Route of Administration, 2023-2030 (Value US$ MN)
4.4.1.2.1.Oral
4.4.1.2.2.Intravenous
4.4.1.2.3.Rectal
4.4.1.2.4.Transdermal
4.4.1.2.5.Topical
4.4.1.3. North America Market Share Analysis, By Country, 2023-2030 (Value US$ MN)
4.4.1.3.1.US
4.4.1.3.2.Canada
4.4.1.3.3.Mexico
4.5. Europe Analgesics Market Segmentation Analysis, 2023-2030 (Value US$ MN)
4.5.1.1. Europe Market Share Analysis, By Type, 2023-2030 (Value US$ MN)
4.5.1.2. Europe Market Share Analysis, By Route of Administration, 2023-2030 (Value US$ MN)
4.5.1.3. Europe Market Share Analysis, By Country, 2023-2030 (Value US$ MN)
4.5.1.3.1.UK
4.5.1.3.2.France
4.5.1.3.3.Germany
4.5.1.3.4.Italy
4.5.1.3.5.Spain
4.5.1.3.6.Sweden
4.5.1.3.7.Austria
4.5.1.3.8.Rest Of Europe
4.6. Asia Pacific Analgesics Market Segmentation Analysis, 2023-2030 (Value US$ MN)
4.6.1.1. Asia Pacific Market Share Analysis, By Type, 2023-2030 (Value US$ MN)
4.6.1.2. Asia Pacific Market Share Analysis, By Route of Administration, 2023-2030 (Value US$ MN)
4.6.1.3. Asia Pacific Market Share Analysis, By Country, 2023-2030 (Value US$ MN)
4.6.1.3.1.China
4.6.1.3.2.India
4.6.1.3.3.Japan
4.6.1.3.4.South Korea
4.6.1.3.5.Australia
4.6.1.3.6.ASEAN
4.6.1.3.7.Rest Of APAC
4.7. South America Analgesics Market Segmentation Analysis, 2023-2030 (Value US$ MN)
4.7.1.1. South America Market Share Analysis, By Type, 2023-2030 (Value US$ MN)
4.7.1.2. South America Market Share Analysis, By Route of Administration, 2023-2030 (Value US$ MN)
4.7.1.3. South America Market Share Analysis, By Country, 2023-2030 (Value US$ MN)
4.7.1.3.1.Brazil
4.7.1.3.2.Argentina
4.7.1.3.3.Rest Of South America
4.8. Middle East and Africa Analgesics Market Segmentation Analysis, 2023-2030 (Value US$ MN)
4.8.1.1. Middle East and Africa Market Share Analysis, By Type, 2023-2030 (Value US$ MN)
4.8.1.2. Middle East and Africa Market Share Analysis, By Route of Administration, 2023-2030 (Value US$ MN)
4.8.1.3. Middle East and Africa Market Share Analysis, By Country, 2023-2030 (Value US$ MN)
4.8.1.3.1.South Africa
4.8.1.3.2.GCC
4.8.1.3.3.Egypt
4.8.1.3.4.Nigeria
4.8.1.3.5.Rest Of ME&A
Chapter 5 Stellar Competition Matrix
5.1.1.Global Stellar Competition Matrix
5.1.2.North America Stellar Competition Matrix
5.1.3.Europe Stellar Competition Matrix
5.1.4.Asia Pacific Stellar Competition Matrix
5.1.5.South America Stellar Competition Matrix
5.1.6.Middle East and Africa Stellar Competition Matrix
5.2. Key Players Benchmarking
5.2.1.Key Players Benchmarking By Application, Pricing, Market Share, Investments, Expansion Plans, Physical Presence and Presence in the Market.
5.3. Mergers and Acquisitions in Industry
5.3.1.M&A by Region, Value and Strategic Intent
Chapter 6 Company Profiles
6.1. Key Players
6.1.1. Pfizer Inc.
6.1.1.1. Company Overview
6.1.1.2. Source Portfolio
6.1.1.3. Financial Overview
6.1.1.4. Business Strategy
6.1.1.5. Key Developments
6.1.2. Pfizer Inc. (USA)
6.1.3. Sun Pharmaceutical Industries, Inc. (Mumbai)
6.1.4. Sanofi SA (France)
6.1.5. AbbVie Inc. (Allergan plc) (USA)
6.1.6. Teva Pharmaceuticals (Jerusalem)
6.1.7. Janssen Pharmaceuticals, Inc. [Johnson & Johnson] (Belgium)
6.1.8. Endo Pharmaceuticals Inc. (Ireland)
6.1.9. Purdue Pharmaceuticals L.P. (USA)
6.1.10.Assertio Therapeutics, Inc. (USA)
6.1.11.Mallinckrodt Pharmaceuticals (USA)
6.1.12.Bayer AG (Germany)
6.1.13.GlaxoSmithKline plc. (UK)
6.1.14.Bausch Health Companies Inc. (Canada)
6.1.15.Novartis AG (Switzerland)
6.2. Key Findings
6.3. Recommendations
